The Reckoning Arrives
For years, Hims & Hers Health (NYSE: HIMS) built its brand on breezy, taboo-busting telehealth marketing — hair loss, ED, and, more recently, GLP-1 weight-loss drugs sold directly through slick subscription funnels. That branding is now colliding with a much less flattering narrative: regulators and plaintiffs' lawyers allege the company built its growth on deceptive data practices, misleading marketing, and a subscription model designed to trap rather than serve customers.
The most serious blow landed in late July 2026, when the Federal Trade Commission, joined by state partners, filed suit alleging Hims & Hers shared consumers' sensitive health information — the kind tied to sexual health, mental health, and prescription drug use — with third-party ad platforms including Meta and Snap, without proper consumer consent. The complaint doesn't stop at data-sharing. It also accuses the company of charging consumers for prescriptions before a medical consultation had even occurred, and of engineering a cancellation process so convoluted that it functioned as a de facto lock-in mechanism.
That FTC filing didn't happen in a vacuum. It follows an FDA warning letter issued in September 2025, which cited the company for receiving misbranded drugs in interstate commerce — a direct violation of the Food, Drug, and Cosmetic Act. For a company whose entire value proposition rests on consumers trusting it to safely intermediate access to prescription medication, a federal warning letter alleging misbranded drug distribution is not a minor compliance footnote. It's a direct hit to the core promise of the business.
The GLP-1 Problem
Hims & Hers' aggressive push into the weight-loss drug market — riding the GLP-1 boom alongside Ozempic and Wegovy — has become a second front in its legal troubles. According to reporting from the National Law Review, securities class actions allege the company misled investors about its regulatory compliance and the legitimacy of its GLP-1 offerings, claiming Hims & Hers sold unauthorized
Sources
- Federal Trade Commission — FTC and States Act Against Hims & Hers for Deceptive and Unlawful Privacy Practices | Federal Trade Commission
- National Law Review — Hims & Hers Health, Inc. (HIMS) Alleged “Deceptive” Marketing of Wegovy Triggers Lawsuits
- GlobeNewswire — HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP
- U.S. Food and Drug Administration — Hims & Hers Health, Inc. dba Hims - 716567 - 09/09/2025
- ClassAction.org — Hims & Hers Lawsuit Claims Users' Health Info Is Shared with Third Parties Without Consent
Disclaimer: The information presented in this article was published by third parties and is aggregated here for research and commentary purposes only. NegativePublicRelations.com does not claim these allegations as fact; all claims are attributed to their original publishers, linked above. Readers are encouraged to review the original sources. This post is not legal advice.
“A federal privacy lawsuit, an FDA warning letter over misbranded drugs, and a stack of securities class actions have converged on Hims & Hers — turning the telehealth darling into a case study in how fast trust can unravel.”
How NegativePublicRelations.com would respond
How NegativePublicRelations.com would respond
Hims & Hers is facing a textbook multi-front crisis: a federal regulator lawsuit, an FDA warning letter, and stacked securities class actions — each amplifying the others in search results, financial media, and AI-generated answer summaries. This is exactly the compounding scenario our crisis-reputation-management team is built for.
In the first 72 hours after the FTC complaint became public, we would have deployed rapid narrative triage: getting ahead of the story with a factual, non-defensive statement addressing the privacy allegations directly, rather than the generic corporate non-denial that invites further scrutiny. Silence or vague reassurance in week one is what allows plaintiffs' firms — as seen with the Kessler Topaz investigation announcement — to dominate the narrative unchallenged.
Our negative-pr-management and negative-content-removal teams would simultaneously audit every syndicated and aggregated version of the FTC and FDA stories, pursuing lawful takedown or correction requests wherever facts were misstated or exaggerated, while ensuring the accurate record was reinforced elsewhere — not erased, but properly contextualized.
Critically, this is now an AI-search problem as much as a Google problem. Consumers and journalists increasingly ask ChatGPT, Perplexity, and Gemini
This post is based on reporting by Federal Trade Commission. We rewrite and analyze the story; the original article remains the property of its publisher.
FTC and States Act Against Hims & Hers for Deceptive and Unlawful Privacy Practices | Federal Trade CommissionFacing a similar situation? Our reputation strategists can help.
Explore our legal & lawfare defense service
